# US 2010/0136026 A1 · Ship Inhibition to Direct Hematopoietic Stem Cells and Induce Extramedullary Hematopoiesis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0136026 A1
- Document ID: US20100136026A1
- Status: Published application
- Kind: A1
- Application number: 12/670,360
- Filed: 2008-09-26
- Published: 2010-06-03
- Earliest claimed: 2007-09-26
- Inventors: William G. Kerr; Amy Hazen
- Web page: https://patentgrep.com/patent/US20100136026A1

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 38/1816: {Erythropoietin [EPO]}
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- C12N 2310/14: interfering nucleic acids [NA]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention concerns inhibition of SHIP expression and/or function in mammalian subjects to direct HSC from the bone marrow to other sites in the body (such as the spleen and/or liver), where they then re-establish blood cell production. The method of the invention can be employed, for example, to rescue or enhance blood cell recovery during bone marrow impairment due to bone-seeking radioisotope exposure, chemotherapy, radiotherapy, infection, or genetic or congenital defects. Preferably, inhibition of SHIP expression and/or function is achieved by administering an effective amount of one or more SHIP inhibitors to the subject. In one embodiment, the subject is suffering from, or at risk of developing, bone marrow failure (such as an aplastic bone marrow failure syndrome). In another embodiment, the subject is suffering from, or at risk of, exposure to a bone-seeking radioisotope. In another embodiment, the subject is suffering from, or at risk of developing, fibrotic or damaged bone marrow due to chemotherapy and/or radiation therapy for cancer.

## Claims

### Claim 1

A method for directing hematopoietic stem cells (HSC) from bone marrow to another site in the body of a person or animal, wherein said method comprises inhibiting SHIP expression and/or SHIP function or activity in a cell of the person or animal, such that the HSC are directed to another site in the body.

### Claim 2 (depends on 1)

The method according to claim 1, wherein SHIP expression is inhibited by RNA interference, or antisense inhibition, or ribozyme inactivation, or an antibody or other molecule that inhibits function or activity of SHIP.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The method according to claim 1, wherein the person or animal has radiation injury manifesting as impaired bone marrow function, or was exposed to, or is at risk of exposure to, a radioisotope that can accumulate in bone.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The method according to claim 1, wherein the person or animal has, or is at risk of developing, fibrotic and/or damaged bone marrow due to chemotherapy and/or radiation therapy.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the person or animal is being treated with one or more other treatments to increase hematopoietic function.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The method according to claim 1, wherein the HSC are directed from bone marrow to the spleen and/or liver.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The method according to claim 1, wherein the person or animal has an infection or a genetic or congenital defect that impairs bone marrow function.

### Claim at position 12

12-13. (canceled)

### Claim 14 (depends on 1)

The method according to claim 1, wherein the person or animal has bone marrow impairment that results from Fanconi anemia, dyskeratosis congenital, Diamond-Blackfan anemia, Shwachman-Diamond syndrome, aplastic anemia, MDS, PRCA, or myelophthisis.

### Claim at position 14

15-16. (canceled)

### Claim 17

A method for rescuing or enhancing blood cell recovery during bone marrow impairment in a person or animal, wherein said method comprises inhibiting SHIP expression and/or SHIP function or activity in a cell of the person or animal.

### Claim at position 16

18-19. (canceled)

### Claim 20 (depends on 17)

The method according to claim 17, wherein the bone marrow impairment results from Fanconi anemia, dyskeratosis congenital, Diamond-Blackfan anemia, Shwachman-Diamond syndrome, aplastic anemia, MDS, PRCA, or myelophthisis.

### Claim 21 (depends on 17)

The method according to claim 17, wherein SHIP expression is inhibited by RNA interference, or antisense inhibition, or ribozyme inactivation, or an antibody or other molecule that inhibits function or activity of SHIP.

### Claim 22

(canceled)

### Claim 23 (depends on 17)

The method according to claim 17, wherein the person or animal has radiation injury manifesting as impaired bone marrow function, or was exposed to, or is at risk of exposure to, a radioisotope that can accumulate in bone.

### Claim 24

(canceled)

### Claim 25 (depends on 17)

The method according to claim 17, wherein the person or animal has, or is at risk of developing, fibrotic and/or damaged bone marrow due to chemotherapy and/or radiation therapy.

### Claim 26 (depends on 17)

The method according to claim 17, wherein the person or animal is being treated with one or more other treatments to increase hematopoietic function.

### Claim 27

(canceled)

### Claim 28 (depends on 17)

The method according to claim 17, wherein HSC are directed from bone marrow to the spleen and/or liver.

### Claim 29

(canceled)

### Claim 30 (depends on 17)

The method according to claim 17, wherein the person or animal has an infection or a genetic or congenital defect that impairs bone marrow function.

### Claim at position 28

31-32. (canceled)

### Claim 33

A method for treating or delaying the onset of impaired bone marrow function in a person or animal, wherein said method comprises administering a therapeutically effective amount of a SHIP inhibitor to a person or animal in need of treatment.

### Claim 34 (depends on 33)

The method according to claim 33, wherein SHIP expression is inhibited by RNA interference, or antisense inhibition, or ribozyme inactivation, or an antibody or other molecule that inhibits function or activity of SHIP.

### Claim 35

(canceled)

### Claim 36 (depends on 33)

The method according to claim 33, wherein the person or animal has radiation injury manifesting as impaired bone marrow function, or was exposed to, or is at risk of exposure to, a radioisotope that can accumulate in bone.

### Claim 37

(canceled)

### Claim 38 (depends on 33)

The method according to claim 33, wherein the person or animal has, or is at risk of developing, fibrotic and/or damaged bone marrow due to chemotherapy and/or radiation therapy.

### Claim 39 (depends on 33)

The method according to claim 33, wherein the person or animal is being treated with one or more other treatments to increase hematopoietic function.

### Claim 40

(canceled)

### Claim 41 (depends on 33)

The method according to claim 33, wherein the HSC are directed from bone marrow to the spleen and/or liver.

### Claim 42

(canceled)

### Claim 43 (depends on 33)

The method according to claim 33, wherein the person or animal has an infection or a genetic or congenital defect that impairs bone marrow function.

### Claim at position 40

44-45. (canceled)

### Claim 46 (depends on 33)

The method according to claim 33, wherein the person or animal has bone marrow impairment that results from Fanconi anemia, dyskeratosis congenital, Diamond-Blackfan anemia, Shwachman-Diamond syndrome, aplastic anemia, MDS, PRCA, or myelophthisis.

### Claim at position 42

47-48. (canceled)
